Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus
- PMID: 17676311
- DOI: 10.1007/s00125-007-0754-5
Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus
Abstract
Aims/hypothesis: In chronic heart failure there is gradual reactivation of vascular tissue angiotensin I (AI) to angiotensin II (AII) conversion over time in patients taking chronic ACE inhibitor therapy. However, it remains unknown whether the same overall phenomenon occurs in other patients taking chronic ACE inhibitor therapy, such as patients with type 2 diabetes mellitus.
Methods: We studied 30 patients with type 2 diabetes mellitus (mean age 43.5 +/- 10.8 years), all of whom received lisinopril (20 mg/day) as part of their normal treatment. Over the course of the 18 month study, we made measurements at 0, 9 and 18 months. These measurements included plasma values for components of the renin-angiotensin-aldosterone system. In addition, we infused AI and AII into the brachial arteries of patients to assess vascular tissue AI to AII conversion.
Results: There were no significant changes in plasma renin activity, ACE, AI, AII or aldosterone during the study. In contrast, vascular AI to AII conversion was significantly (p = 0.01) greater at 18 months than at 0 months. There was no change over time in the response to infused AII.
Conclusions/interpretation: We have shown in vivo that vascular tissue AI to AII conversion gradually increases over time in patients with type 2 diabetes being treated with lisinopril. Further studies are required to determine whether this reactivation detracts from the cardioprotective effects of chronic ACE inhibitor therapy in diabetic patients, and if so, how best to overcome it.
Similar articles
-
Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure.J Am Coll Cardiol. 2002 Mar 6;39(5):767-75. doi: 10.1016/s0735-1097(02)01689-3. J Am Coll Cardiol. 2002. PMID: 11869839 Clinical Trial.
-
How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?Heart. 1999 Jul;82(1):57-61. doi: 10.1136/hrt.82.1.57. Heart. 1999. PMID: 10377310 Free PMC article.
-
[The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].Ter Arkh. 2008;80(1):49-52. Ter Arkh. 2008. PMID: 18326228 Russian.
-
Diabetes mellitus, the renin-angiotensin system, and angiotensin-converting enzyme inhibition.Nephron. 1990;55 Suppl 1:10-20. doi: 10.1159/000186029. Nephron. 1990. PMID: 2189073 Review.
-
Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy.J Diabetes Complications. 1996 May-Jun;10(3):133-5. doi: 10.1016/1056-8727(96)00031-1. J Diabetes Complications. 1996. PMID: 8807457 Review.
Cited by
-
Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors.PLoS One. 2016 Sep 23;11(9):e0163341. doi: 10.1371/journal.pone.0163341. eCollection 2016. PLoS One. 2016. PMID: 27662362 Free PMC article.
-
Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney.Am J Physiol Endocrinol Metab. 2012 Apr 15;302(8):E1016-24. doi: 10.1152/ajpendo.00515.2011. Epub 2012 Feb 7. Am J Physiol Endocrinol Metab. 2012. PMID: 22318946 Free PMC article.
-
Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.J Gastroenterol Hepatol. 2008 Sep;23(9):1327-38. doi: 10.1111/j.1440-1746.2008.05461.x. Epub 2008 Jun 28. J Gastroenterol Hepatol. 2008. PMID: 18557800 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous